The online version of this article (https://doi.org/10.1007/s00066-018-1402-3) contains supplementary material, which is available to authorized users.
Accurate prostate cancer (PCa) detection is essential for planning focal external beam radiotherapy (EBRT). While biparametric MRI (bpMRI) including T2-weighted (T2w) and diffusion-weighted images (DWI) is an accurate tool to localize PCa, its value is less clear in the case of additional androgen deprivation therapy (ADT). The aim of this study was to investigate the value of a textural feature (TF) approach on bpMRI analysis in prostate cancer patients with and without neoadjuvant ADT with respect to future dose-painting applications.
28 PCa patients (54–80 years) with (n = 14) and without (n = 14) ADT who underwent bpMRI with T2w and DWI were analyzed retrospectively. Lesions, central gland (CG), and peripheral zone (PZ) were delineated by an experienced urogenital radiologist based on localized pre-therapeutic histopathology. Histogram parameters and 20 Haralick TF were calculated. Regional differences (i. e., tumor vs. PZ, tumor vs. CG) were analyzed for all imaging parameters. Receiver-operating characteristic (ROC) analysis was performed to measure diagnostic performance to distinguish PCa from benign prostate tissue and to identify the features with best discriminative power in both patient groups.
The obtained sensitivities were equivalent or superior when utilizing the TF in the no-ADT group, while specificity was higher for the histogram parameters. However, in the ADT group, TF outperformed the conventional histogram parameters in both specificity and sensitivity. Rule-in and rule-out criteria for ADT patients could exclusively be defined with the aid of TF.
The TF approach has the potential for quantitative image-assisted boost volume delineation in PCa patients even if they are undergoing neoadjuvant ADT.
Table S1 Details on T2w and ADC scanning protocols of each patient66_2018_1402_MOESM1_ESM.pdf
Table S2 Characteristic clinical parameters of the two patient sub-groups66_2018_1402_MOESM2_ESM.pdf
Figure S1 The decision tree diagrams for both patient groups and both healthy tissue ROIs66_2018_1402_MOESM3_ESM.pdf
Lips IM, van der Heide UA, Haustermans K et al (2011) Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 12:255. https://doi.org/10.1186/1745-6215-12-255 CrossRefPubMedPubMedCentral
Monninkhof EM, van Loon JWL, van Vulpen M et al (2018) Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiother Oncol. https://doi.org/10.1016/j.radonc.2017.12.022 CrossRefPubMed
Andrzejewski P, Kuess P, Knäusl B et al (2015) Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiother Oncol. https://doi.org/10.1016/j.radonc.2015.07.028 CrossRefPubMed
Perera M, Krishnananthan N, Lindner U, Lawrentschuk N (2016) An update on focal therapy for prostate cancer. Nat Rev Urol 13:641 CrossRef
Rose BS, Chen M, Wu J, et al (2016) Androgen deprivation therapy use in the setting of high-dose radiation therapy and the risk of prostate cancer-specific mortality stratified by the extent of competing mortality. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2016.08.014 CrossRefPubMed
South A, Parulekar WR, Sydes MR et al (2016) Estimating the impact of randomised control trial results on clinical practice: results from a survey and modelling study of androgen deprivation therapy plus radiotherapy for locally advanced prostate cancer. Eur Urol Focus 2:276–283. https://doi.org/10.1016/j.euf.2015.11.004 CrossRefPubMedPubMedCentral
Groenendaal G, Van Vulpen M, Pereboom SR et al (2012) The effect of hormonal treatment on conspicuity of prostate cancer: implications for focal boosting radiotherapy. Radiother Oncol 103:233–238. https://doi.org/10.1016/j.radonc.2011.12.007 CrossRefPubMed
Lemaître G, Martí R, Freixenet J et al (2015) Computer-aided detection and diagnosis for prostate cancer based on mono and multi-parametric MRI : a review. Comput Biol Med 60:8–31. https://doi.org/10.1016/j.compbiomed.2015.02.009 CrossRefPubMed
Brynolfsson P, Löfstedt T, Asklund T et al (2018) Gray-level invariant Haralick texture features (PV-0527). Radiother Oncol 127:275–276 CrossRef
Bart S, Mozer P, Hemar P, Lenaour G, Comperat E, Renard-Penna R, Chartier-Kastler E, Troccaz J (2005) MRI-histology registration in prostate cancer. In: Proc Surgetica, pp 361–367
Xiao G, Bloch BN, Chappelow J et al (2011) Determining histology-MRI slice correspondences for defining MRI-based disease signatures of prostate cancer. Comput Med Imaging Graph 35:568–578. https://doi.org/10.1016/j.compmedimag.2010.12.003 CrossRefPubMed
- Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer
- Springer Berlin Heidelberg
Strahlentherapie und Onkologie
Journal of Radiation Oncology, Biology, Physics
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
Neu im Fachgebiet Onkologie
Mail Icon II